Amyris, Inc.

Amyris is in a confirmed-plan posture after the Delaware bankruptcy court approved its third amended reorganization plan on February 7, 2024, leaving the case focused on plan implementation, claim resolution, trust mechanics, post-confirmation governance, and final professional-fee processes under the confirmation orderDkt. 1251.

The company entered chapter 11 on August 9, 2023, after an overleveraged capital structure and operating losses overtook its synthetic-biology platform, consumer-brand portfolio, and strategic-partner revenue model. The first-day record described a business with nearly 700 patents, commercialized molecules, and facilities in California, North Carolina, and Brazil, but also declining revenue, unprofitable business segments, litigation risk, strained vendor support, approximately $295 million of Foris secured debt, roughly $74 million owed across DSM Finance tranches, $690 million of convertible senior notes, and about $95 million of trade payables as of July 31, 2023 Kieftenbeld first-day declarationDkt. 18.

The restructuring was shaped by sponsor-linked liquidity and a fast path to either a consensual deal or sale alternative. Euagore, an affiliate of Foris Ventures, committed $190 million in DIP financing, while the debtors pursued a chapter 11 process designed to preserve operations and enterprise value long enough to resolve the balance sheet and key commercial relationships Kieftenbeld first-day declarationDkt. 18. By January 2024, the debtors had moved to a reorganization plan built around 14 claim classes, a $190 million DIP facility, an exit first-lien facility of up to $160 million, treatment alternatives for Foris secured claims, a $2 million creditor trust, cancellation of existing securities, delisting, and a private-company go-forward structure for reorganized Amyris .